Welcome to our dedicated page for Qualigen Therapeutics SEC filings (Ticker: QLGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AIxCrypto Holdings filings document the completed rebrand from Qualigen Therapeutics and the company’s transition into AI and blockchain-enabled digital infrastructure. Recent Form 8-K disclosures cover operating and financial results, Regulation FD updates, material agreements, and corporate developments related to Real World Asset tokenization, AI agents, Embodied AI infrastructure, and digital-asset strategy.
The filing record also details private-placement financing, common and preferred stock matters, shareholder voting, board and committee governance, and amendments to entrusted investment and securities purchase agreements involving Faraday Future securities. These disclosures show how the company reports capital structure, control relationships, and strategic execution after its business transformation.
Qualigen Therapeutics, Inc. (NASDAQ: QLGN) filed a Form 8-K announcing a board-level governance change effective June 20 2025. Independent director Robert B. Lim was appointed Chair of the Audit Committee, succeeding Graydon Bensler, who will remain a committee member. The board affirmed that Lim meets Nasdaq Rule 5605 and SEC Rule 10A-3 independence criteria and is deemed an “audit committee financial expert” under Regulation S-K Item 407(d)(5). The filing states there are no related-party transactions or special arrangements connected to Lim’s elevation. No other management changes, financial results, or transactions were disclosed.